Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance

被引:60
作者
Catto, JWF
Hartmann, A
Stoehr, R
Bolderson, E
Rehman, I
Rosario, DJ
Hamdy, FC
Meuth, M
机构
[1] Univ Sheffield, Acad Urol Unit, Inst Canc Studies, Sheffield, S Yorkshire, England
[2] Univ Regensburg, Inst Pathol, D-8400 Regensburg, Germany
[3] Univ Regensburg, Dept Urol, D-8400 Regensburg, Germany
基金
英国医学研究理事会;
关键词
bladder; bladder neoplasms; urothelium; microsatellite repeats; methylation;
D O I
10.1016/S0022-5347(06)00256-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: UC is a disease of the entire urothelium, characterized by multiplicity and multifocality. The clonal relationship among multiple UCs has implications regarding adjuvant chemotherapy. It has been investigated in studies of chromosomal alteration and single gene mutation. However, these genetic changes can occur in unrelated tumors under similar carcinogenic selection pressures. Tumors with high MSI have numerous DNA mutations, of which many provide no selection benefit. While these tumors represent an ideal model for studying UC clonality, their low frequency has prevented their previous investigation. Materials and Methods: We investigated 32 upper and lower urinary tract UCs with high MSI and 4 nonUC primary cancers in 9 patients. We used the high frequency and specificity of individual DNA mutations in these tumors (MSI at 17 loci) and the early timing of epigenetic events (methylation of 7 gene promoters) to investigate tumor clonality. Results: Molecular alterations varied among tumors from different primary organs but they appeared related in the UCs of all 9 patients. While 7 patients had a high degree of concordance among UCs, in 2 the UCs shared only a few similar alterations. Genetic and epigenetic abnormalities were frequently found in normal urothelial samples. Conclusions: Multiple UCs in each patient appeared to arise from a single clone. The molecular order of tumor development varied from the timing of clinical presentation and suggested that residual malignant cells persist in the urinary tract despite apparent curative surgery. These cells lead to subsequent tumor relapse and new methods are required to detect and eradicate them.
引用
收藏
页码:2323 / 2330
页数:8
相关论文
共 19 条
[1]  
Boland CR, 1998, CANCER RES, V58, P5248
[2]   Distinct patterns of microsatellite instability are seen in tumours of the urinary tract [J].
Catto, JWF ;
Azzouzi, AR ;
Amira, N ;
Rehman, I ;
Feeley, KM ;
Cross, SS ;
Fromont, G ;
Sibony, M ;
Hamdy, FC ;
Cussenot, O ;
Meuth, M .
ONCOGENE, 2003, 22 (54) :8699-8706
[3]   Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma [J].
Catto, JWF ;
Azzouzi, AR ;
Rehman, I ;
Feeley, KM ;
Cross, SS ;
Amira, N ;
Fromont, G ;
Sibony, M ;
Cussenot, O ;
Meuth, M ;
Hamdy, FC .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2903-2910
[4]  
Dalbagni G, 2001, CLIN CANCER RES, V7, P2797
[5]  
FRYFE R, 2000, NEW ENGL J MED, V342, P69
[6]   Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract [J].
Hafner, C ;
Knuechel, R ;
Zanardo, L ;
Dietmaier, W ;
Blaszyk, H ;
Cheville, J ;
Hofstaedter, F ;
Hartmann, A .
ONCOGENE, 2001, 20 (35) :4910-4915
[7]   Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies [J].
Hafner, C ;
Knuechel, R ;
Stoehr, R ;
Hartmann, A .
INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (01) :1-6
[8]  
Hartmann A, 2002, CANCER RES, V62, P6796
[9]   Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma [J].
Herman, JG ;
Umar, A ;
Polyak, K ;
Graff, JR ;
Ahuja, N ;
Issa, JPJ ;
Markowitz, S ;
Willson, JKV ;
Hamilton, SR ;
Kinzler, KW ;
Kane, MF ;
Kolodner, RD ;
Vogelstein, B ;
Kunkel, TA ;
Baylin, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6870-6875
[10]  
Louhelainen J, 2000, INT J CANCER, V87, P522